CEO Corner

The standard parting advice at every hospital discharge is simple: “Be sure to check in with your doctor tomorrow.” But for many, the path from the hospital bed to the home front is a “dizzying process” fraught with logistical, financial, and emotional hurdles. In his latest “Checking In” column, Waveny LifeCare Network CEO Russell Barksdale, Jr. examines the hidden crisis of post-hospital recovery, where 40% of patients over age 50 return to empty homes and nearly one-fifth experience an adverse medical event within weeks.

The cost of health insurance has shifted from a staple workplace benefit to a primary source of economic anxiety for Connecticut families and businesses. In this critical update, Waveny LifeCare Network CEO Russell Barksdale, Jr. examines the sobering projections for 2026, where insurers are seeking double-digit premium increases—some as high as 26% for individual plans.

Is a wagging tail or a soft purr the secret to a longer, healthier life? In this lighthearted yet insightful commentary, Waveny LifeCare Network CEO Russell Barksdale, Jr. explores the profound clinical impact of pet ownership and animal-assisted therapy. Beyond the simple joy of companionship, Barksdale dives into the data linking pets to lower blood pressure, reduced stress hormones, and a decreased risk of cardiovascular disease.

For the fourth consecutive year, Medicare and commercial insurers are slashing reimbursement rates for home health services—a move that Waveny LifeCare Network CEO Russell Barksdale, Jr. warns is systematically dismantling the very system designed to keep seniors independent. Despite the fact that over 90% of older adults prefer to age in place, these relentless cuts are turning a cost-effective healthcare model into an “unsustainable illusion.”

The quest for affordable medication in the United States has evolved from a grassroots movement into a complex geopolitical stalemate. In this insightful analysis, Waveny LifeCare Network CEO Russell Barksdale, Jr. traces the trajectory of the American pharmaceutical supply chain—from the late 1990s, when a million Americans looked to Canada for price relief, to our modern-day reliance on Chinese manufacturing for essential drug ingredients.

While GLP-1 medications like Ozempic and Wegovy have revolutionized the landscape of weight management and diabetes care, a growing trend of early discontinuation is raising questions among healthcare providers. In this edition of the CEO Corner, Waveny LifeCare Network President and CEO Russell Barksdale, Jr. explores the complex factors driving patients to stop these treatments—from high out-of-pocket costs and insurance barriers to the “perception of short-term use.”